World apheresis registry report

Stegmayr, Bernd; Pták, Jan; Wíkström, Björn

doi:10.1016/j.transci.2006.06.009

Cited by 43 publications

(46 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our cohort, there were a few cases of hypotension and hypocalcemia (during citrate anticoagulation), and some rare clotting problems due to high blood viscosity. Similarly low incidences of adverse effects during apheresis procedures are reported from the world apheresis registry, with the exception of hypocalcemia in centers where calcium substitution is not routinely used [27], [28].…”

Section: Discussionsupporting

confidence: 55%

Factors Affecting Outcome in Acute Hypertriglyceridemic Pancreatitis Treated with Plasma Exchange: An Observational Cohort Study

et al. 2014

View full text Add to dashboard Cite

ObjectivesThe optimal therapy for hypertriglyceridemic acute pancreatitis, especially the role of plasma exchange (PE), is not entirely clear. The aim of our large, single-center, observational, cohort study was to analyze the factors affecting outcome in hypertriglyceridemic pancreatitis treated with PE.MethodsWe included 111 episodes of hypertriglyceridemic pancreatitis treated with PE, which occurred in 103 different patients. The Acute Physiology and Chronic Health Evaluation (APACHE) II score, triglycerides, delay to first PE, and PE treatment details were retrospectively obtained from the patients’ records. The main outcome measures were length of hospitalization and in-hospital mortality.ResultsThe patients were 47±9 years old and the median APACHE II score at first PE was 4 (inter-quartile range (IQR) 2–7). There was a seasonal variation in the incidence of hypertriglyceridemic pancreatitis, and the recurrence rate was 1.6% per year. Triglycerides at presentation did not correlate with APACHE II or influence the outcome. The mean reduction in triglycerides during PE was 59% (from 44±31 to 18±15 mmol/l), which was twice the reduction observed during conservative treatment (27% daily). The median hospital stay was 16 days (IQR 10–24) and in-hospital mortality was 5%. The median delay to first PE was 35 hours (IQR 24–52), and there was no difference in mortality in the early and late PE groups (7% vs. 6%, p = 0.79). The group with citrate anticoagulation during PE had a significantly lower mortality than the group with heparin anticoagulation (1% vs. 11%, p = 0.04), and citrate was an independent predictor also in the multivariate model (p = 0.049).ConclusionsPE effectively reduced serum triglycerides faster than could be expected with conservative treatment. The delay in PE therapy did not influence survival. We found that citrate anticoagulation during PE was associated with reduced mortality, which should be confirmed in a randomized study.

show abstract

Section: Discussionsupporting

confidence: 55%

Factors Affecting Outcome in Acute Hypertriglyceridemic Pancreatitis Treated with Plasma Exchange: An Observational Cohort Study

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Adverse events reported in association with heparin anticoagulation are hemorrhagic in nature, usually at the vascular access site of insertion (0.7%) [21,27,36]. There have been few case reports of heparin-induced thrombocytopenia (HIT) associated with TA procedures, these presented as thrombocytopenia, venous thrombosis, and pulmonary emboli [37].…”

Section: Clinical Adverse Events During Therapeutic Apheresismentioning

confidence: 99%

“…Overall, FFP is associated with a two-fold higher risk of total adverse events relative to albumin, but no difference in treatment interruption has been reported between replacement colloid types [25,27]. In TA procedures FFP is used predominantly for the treatment thrombotic thrombocytopenic purpura (TTP), and FFP replaces the depleted cleaving protease, ADAMTS-13.…”

Section: Clinical Adverse Events During Therapeutic Apheresismentioning

confidence: 99%

“…The incidence of total adverse events associated with the vascular access is low in most series, 1%. Complications include infection, thrombosis, hemmorhage, pneumothorax, and mechanical complications [21,27,36]. In the International Apheresis Registry, however, vascular access complications were the most common type of adverse events, (38%).…”

Section: Clinical Adverse Events During Therapeutic Apheresismentioning

confidence: 99%

See 1 more Smart Citation

Introduction and overview of therapeutic apheresis

Okafor

Ward

Mokrzycki

et al. 2010

J of Clinical Apheresis

View full text Add to dashboard Cite

“…To understand international perspectives and regional differences, international apheresis registries have been established by the International Society for Apheresis (ISFA) and the World Apheresis Association (WAA) [9][10][11][12][13][14], and more recently, to increase the number of participating centers and to reduce costs, these apheresis registries have been established on the internet [3,[11][12][13][14][15].…”

Section: Introductionmentioning

confidence: 99%